Efegatran

Drug Profile

Efegatran

Alternative Names: Efegatran sulfate; GYKI 14766; LY 294468

Latest Information Update: 01 Aug 2002

Price : $50

At a glance

  • Originator Eli Lilly; IVAX Drug Research Institute
  • Developer Eli Lilly
  • Class Anticoagulants; Antithrombotics; Oligopeptides; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronary thrombosis; Myocardial infarction; Thrombosis

Most Recent Events

  • 11 Jan 2000 A study has been added to the Ischaemic Heart Disease and Thromboses therapeutic trials sections
  • 26 Oct 1999 IVAX Corporation has acquired the Institute for Drug Research
  • 11 Oct 1999 A study has been added to the adverse events, and Ischaemic Heart Disease and Thromboses pharmacodynamics and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top